Q2 2025 Recap: Cardiology News and Updates
3 Articles
3 Articles
FDA approves Hikma's Tyzavan for multiple infections
Tyzavan is indicated for the treatment of several serious infections in adults and children one month and above, including septicemia, infective endocarditis, skin and skin structure infections, bone The post FDA approves Hikma’s Tyzavan for multiple infections appeared first on Pharmaceutical Business review.
FDA Novel Drug Therapy Approvals for 2025 | Quarter 2 - BioPatrika
Novel Drug Approvals for 2025 Each year, the U.S. Food and Drug Administration (FDA) reviews and approves a select group of new medications known as “novel” drugs—those that have never before been approved or marketed in the United States. These drugs often represent significant scientific and clinical advances, offering new treatment options for diseases with […] The post FDA Novel Drug Therapy Approvals for 2025 | Quarter 2 appeared first on B…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium